PRAME expression and clinical outcome of breast cancer

被引：0
作者：
M T Epping
A A M Hart
A M Glas
O Krijgsman
R Bernards
机构：
[1] The Netherlands Cancer Institute,Division of Molecular Carcinogenesis and Centre for Biomedical Genetics
[2] The Netherlands Cancer Institute,Department of Radiation Oncology
[3] Agendia BV,undefined
来源：
British Journal of Cancer | 2008年 / 99卷
关键词：
PRAME; tumour antigen; prognosis; metastasis; survival; microarray;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The tumour antigen PReferentially expressed Antigen of MElanoma (PRAME) is expressed in a variety of malignancies, including breast cancer. We have analysed PRAME gene expression in relation to clinical outcome for 295 primary breast cancer patients. Kaplan–Meier survival curves show a correlation of PRAME expression levels with increased rates of distant metastases and decreased overall patient survival. This correlation existed both for the entire patient group (n=295) and for the subgroup of patients (n=185) who did not receive adjuvant chemotherapy. Multivariable analysis indicated that PRAME is an independent marker of shortened metastasis-free interval in patients who did not receive adjuvant chemotherapy. PRAME expression was associated with tumour grade and negative oestrogen receptor status. We conclude that PRAME expression is a prognostic marker for clinical outcome of breast cancer, independent of traditional clinicopathological markers.
引用
收藏
页码：398 / 403
页数：5
相关论文
共 172 条
  • [1] Bernards R(2002)A progression puzzle Nature 418 823-7694
  • [2] Weinberg RA(2003)Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes Oncogene 22 7687-1192
  • [3] Boon K(2006)Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 98 1183-365
  • [4] Edwards JB(2008)Prevalence and prognostic and predictive relevance of PRAME in breast cancer Breast Cancer Res Treat 109 359-10642
  • [5] Siu IM(2006)A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer Cancer Res 66 10639-847
  • [6] Olschner D(2005)The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling Cell 122 835-347
  • [7] Eberhart CG(2001)Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer Nat Biotechnol 19 342-208
  • [8] Marra MA(1997)Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor Immunity 6 199-2190
  • [9] Strausberg RL(2002)Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal–epithelial transition Am J Pathol 160 2181-4095
  • [10] Riggins GJ(1998)Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 58 4090-4313
12345678910